Calliditas Therapeutics Showcases Groundbreaking Research at ASN Kidney Week 2025
Calliditas Therapeutics, a biopharmaceutical company under Asahi Kasei, has made headlines as they prepare to present critical findings at the 2025 American Society of Nephrology Kidney Week, slated for November 6-9 in Houston, Texas. The presentations are set to provide an exciting glimpse into ongoing advancements in the treatment of immunoglobulin A nephropathy (IgAN) as well as Alport Syndrome, a rare genetic disorder impacting renal health.
A significant portion of the presentations will focus on the secondary analyses from the Phase 3 NefIgArd study, which examines Nefecon, marketed as TARPEYO in the United States. This delayed-release budesonide capsule is designed for IgAN patients at risk for disease progression. In addition to the NefIgArd study data, Calliditas will introduce initial demographics from the PERFORM registry, which tracks IgAN patients who are undergoing treatment with TARPEYO. The inclusion of real-world treatment evidence derived from the Veterans Health Administration and the Cure Glomerulopathy Network (CureGN) registry adds further depth to their research narrative.
One of the most anticipated presentations will include findings from a Phase 2a randomized, double-blind, placebo-controlled trial of setanaxib, aimed at treating Alport Syndrome. Scheduled for a High-Impact Clinical Trials session on November 8, this study discusses a rare genetic kidney disease caused by mutations in collagen type IV genes, which could drastically affect kidney function. With eight abstracts accepted for presentation, including a high-impact clinical trial, Calliditas' contributions to the Kidney Week are sure to spark dialogues among kidney health professionals.
Among the specific presentations, the highly anticipated abstract No. 3345 will share safety and preliminary efficacy results related to setanaxib in patients with Alport Syndrome on November 8, while another presentation will focus on how Nefecon affects proteinuria levels in IgAN patients. The conference will offer experts a platform to share their insights, engage in discussions, and collaborate for the advancement of nephrology.
This annual ASN Kidney Week is renowned as the leading event for nephrology, gathering a rich mix of thought leaders, researchers, and healthcare professionals. It serves as a hub for exchanging innovative ideas and the latest scientific breakthroughs, which could shape the future of kidney care and research. The opportunity for Calliditas to share their findings at such an influential forum underscores their commitment to addressing unmet medical needs in the kidney health sector.
Furthermore, TARPEYO has received attention due to its innovative formulation aimed at targeting the specific site of disease manifestation in IgAN. Patients with IgAN often experience progressive kidney damage, which can lead to end-stage renal failure. Through ongoing research and development, Calliditas hopes to refine and expand therapeutic options for those afflicted by this chronic condition.
Secondary to their clinical studies, the biopharma company is also focused on educating and updating healthcare professionals on the progressive nature of these kidney diseases, ensuring they remain informed of new developments and treatment protocols. Calliditas Therapeutics exemplifies the kind of innovation that fosters advancements in the healthcare landscape, particularly in specialized fields like nephrology.
In summary, Calliditas Therapeutics is set to unveil significant findings at ASN Kidney Week 2025 that could lead to better management strategies for patients suffering from IgAN and Alport Syndrome. As the nephrology community looks forward to engaging with this research, it is clear that continued investment in kidney disease research is critical to the future of kidney health.
A significant portion of the presentations will focus on the secondary analyses from the Phase 3 NefIgArd study, which examines Nefecon, marketed as TARPEYO in the United States. This delayed-release budesonide capsule is designed for IgAN patients at risk for disease progression. In addition to the NefIgArd study data, Calliditas will introduce initial demographics from the PERFORM registry, which tracks IgAN patients who are undergoing treatment with TARPEYO. The inclusion of real-world treatment evidence derived from the Veterans Health Administration and the Cure Glomerulopathy Network (CureGN) registry adds further depth to their research narrative.
One of the most anticipated presentations will include findings from a Phase 2a randomized, double-blind, placebo-controlled trial of setanaxib, aimed at treating Alport Syndrome. Scheduled for a High-Impact Clinical Trials session on November 8, this study discusses a rare genetic kidney disease caused by mutations in collagen type IV genes, which could drastically affect kidney function. With eight abstracts accepted for presentation, including a high-impact clinical trial, Calliditas' contributions to the Kidney Week are sure to spark dialogues among kidney health professionals.
Among the specific presentations, the highly anticipated abstract No. 3345 will share safety and preliminary efficacy results related to setanaxib in patients with Alport Syndrome on November 8, while another presentation will focus on how Nefecon affects proteinuria levels in IgAN patients. The conference will offer experts a platform to share their insights, engage in discussions, and collaborate for the advancement of nephrology.
This annual ASN Kidney Week is renowned as the leading event for nephrology, gathering a rich mix of thought leaders, researchers, and healthcare professionals. It serves as a hub for exchanging innovative ideas and the latest scientific breakthroughs, which could shape the future of kidney care and research. The opportunity for Calliditas to share their findings at such an influential forum underscores their commitment to addressing unmet medical needs in the kidney health sector.
Furthermore, TARPEYO has received attention due to its innovative formulation aimed at targeting the specific site of disease manifestation in IgAN. Patients with IgAN often experience progressive kidney damage, which can lead to end-stage renal failure. Through ongoing research and development, Calliditas hopes to refine and expand therapeutic options for those afflicted by this chronic condition.
Secondary to their clinical studies, the biopharma company is also focused on educating and updating healthcare professionals on the progressive nature of these kidney diseases, ensuring they remain informed of new developments and treatment protocols. Calliditas Therapeutics exemplifies the kind of innovation that fosters advancements in the healthcare landscape, particularly in specialized fields like nephrology.
In summary, Calliditas Therapeutics is set to unveil significant findings at ASN Kidney Week 2025 that could lead to better management strategies for patients suffering from IgAN and Alport Syndrome. As the nephrology community looks forward to engaging with this research, it is clear that continued investment in kidney disease research is critical to the future of kidney health.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.